AdvanDx Pockets $15M in Series C Funds; Will Use Cash to Drive S&M, R&D

Sep 19, 2007

NEW YORK (GenomeWeb News) — Molecular diagnostics developer AdvanDx will use a $15 million blast of Series C financing from BioMérieux and two existing investors to push sales and marketing efforts and to expand its R&D facilities, the company said yesterday.

Joining BioMérieux in the financing is LD Pensions and Scandinavian Life Science Venture.

AdvanDx makes a suite of diagnostics for detecting, identifying, and managing pathogens and infections, including the PNA FISH and Evigene tests, which detect antibiotic-resistant bacteria.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

Breaking News

The Scan

More to Go Around

Congress approved a bill Friday that would increase the US National Institutes of Health's funding by $2 billion for fiscal year 2019.

Call for Ban

UK's Labour Party calls for a ban on non-invasive prenatal testing for determining sex, BBC News reports.

To Worry or Not?

Sarah Lawrence College's Laura Hercher warns in a New York Times op-ed that more people are going to need help figuring out what their consumer genetic testing results mean.

This Week in PLOS

In PLOS this week: intra-tumor heterogeneity patterns, genomic analysis of Thoroughbred horse origins, and more.

Main menu